In this eClinical Forum webinar presentation, Dr. Jules Mitchel, President of Target Health, facilitated the discussion on the future landscape and regulatory concerns of paperless clinical trials and clinical trial design incorporating mobile tools.
Dr. Jules Mitchel at NY Medical College, October 2014
Nobody wants to receive a Form FDA 483 after an FDA inspection of a clinical site, drug/device company, manufacturing plant or other entities subject to regulatory inspections. Nevertheless, while inspection findings are inevitable, they are not intended to be "the end of the world."
Target Health, Inc. participated in study design, regulatory activities, and data management, and reviewed all versions of the manuscript for this clinical trial.